Vasohibin-1 is identified as a master-regulator of endothelial cell apoptosis using gene network analysis. by Affara, Muna et al.
Affara et al. BMC Genomics 2013, 14:23
http://www.biomedcentral.com/1471-2164/14/23RESEARCH ARTICLE Open AccessVasohibin-1 is identified as a master-regulator of
endothelial cell apoptosis using gene network
analysis
Muna Affara1, Debbie Sanders1, Hiromitsu Araki2, Yoshinori Tamada3, Benjamin J Dunmore1, Sally Humphreys1,
Seiya Imoto3, Christopher Savoie2, Satoru Miyano3, Satoru Kuhara4, David Jeffries5, Cristin Print6,7*
and D Stephen Charnock-Jones1,8*Abstract
Background: Apoptosis is a critical process in endothelial cell (EC) biology and pathology, which has been
extensively studied at protein level. Numerous gene expression studies of EC apoptosis have also been performed,
however few attempts have been made to use gene expression data to identify the molecular relationships and
master regulators that underlie EC apoptosis. Therefore, we sought to understand these relationships by generating
a Bayesian gene regulatory network (GRN) model.
Results: ECs were induced to undergo apoptosis using serum withdrawal and followed over a time course in
triplicate, using microarrays. When generating the GRN, this EC time course data was supplemented by a library of
microarray data from EC treated with siRNAs targeting over 350 signalling molecules.
The GRN model proposed Vasohibin-1 (VASH1) as one of the candidate master-regulators of EC apoptosis with
numerous downstream mRNAs. To evaluate the role played by VASH1 in EC, we used siRNA to reduce the
expression of VASH1. Of 10 mRNAs downstream of VASH1 in the GRN that were examined, 7 were significantly up-
or down-regulated in the direction predicted by the GRN.Further supporting an important biological role of VASH1
in EC, targeted reduction of VASH1 mRNA abundance conferred resistance to serum withdrawal-induced EC death.
Conclusion: We have utilised Bayesian GRN modelling to identify a novel candidate master regulator of EC
apoptosis. This study demonstrates how GRN technology can complement traditional methods to hypothesise the
regulatory relationships that underlie important biological processes.
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The explosion of systems biology in recent years, facili-
tated by sequencing of the human genome [1,2] and the
development of high throughput methods to rapidly
characterise and quantify biological systems [3-6], has
promoted understanding of complex biological and
pathological processes. Gene regulatory networks (GRN)
represent a systems biology approach, taking advantage
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reproduction in any medium, provided the orgenerated by modern high throughput methods such as
microarrays or RNAseq, to holistically model interac-
tions between molecules in cells and tissues. GRN are
usually displayed as directed graphs - nodes represent
mRNA abundance and edges represent some form of
regulatory relationship between the nodes. The reverse
engineering of GRN from gene expression data has been
used to understand molecular interactions in both bac-
terial and lower eukaryotic organisms, as well as in more
complex mammalian systems. GRN employ simple cor-
relation [7] or Boolean [8] methods, algorithms based on
mutual information [9,10] as well as Bayesian methods.
Computational frameworks have been generated to sim-
ultaneously perform several types of GRN analysis [11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ference of causal relationships between mRNAs in noisy
microarray data [12,13]. In Bayesian GRN, the probabil-
ity of the abundance of each mRNA node is modelled
using a function that takes as its inputs the abundance
of the node's parent mRNAs. The edges in a Bayesian
GRN can represent hidden protein, non-coding RNA or
metabolite-based regulatory relationships [14]. There-
fore, Bayesian GRN can in theory capture information
about a subset of the complex cellular regulatory cir-
cuitry [15]. Many GRN developed to date have had a
‘scale free’ structure [10,16], in which a small number of
“hub” RNAs can be identified that are connected to large
numbers of downstream RNAs in the networks. These
hub RNAs are candidate master-regulators of transcrip-
tion and other cellular processes. Their identification is
based on relationships in the data between the hub RNA
and their downstream RNAs in the GRN structure,
which are usually referred to as "children". Therefore,
the amount of data behind the identification of hub
RNAs is much greater than the amount of data behind
the identification of individual edges, and correct identi-
fication of hubs may be easier in theory than the correct
identification of individual edges.
Apoptosis is pivotal for normal EC function [17], and
the dysregulation of endothelial apoptosis is a key step
in the development of numerous pathologies [18], includ-
ing cardiovascular disease [19-21] and tumourogenesis
[22-25]. Understanding the regulatory events occurring
during this process in a holistic manner may provide
insight into normal vascular development and mainten-
ance, as well as vascular pathologies. Although there has
been extensive characterisation of the EC proteins
involved in apoptotic pathways [26-28], there have been
fewer investigations into regulation of the transcriptome
in ECs undergoing apoptosis [17,29].
To begin to address this issue, our group have
previously used Bayesian GRN to identify molecular
interactions involved in survival factor deprivation (SFD)-
induced EC apoptosis and cell cycle arrest [18]. This
previous study used micorarray data over a triplicated
eight time point SFD time course. Previous studies have
illustrated the value of supplementing time series data
with gene disruption data (e.g. [30]). Since at the time we
were especially interested in regulation of the cell cycle, in
this previous work the time series data was supplemented
by eight microarrays from EC cultures treated with
siRNAs targeting molecules associated with the cell cycle.
This analysis identified several GRN master regulator
RNAs including the γ-amino butyric acid (GABA)-
Receptor Associated Protein (GABARAP) [18].
In theory, the greater the volume of high-quality
siRNA data used to supplement time course data, and
the broader the range of RNAs targeted by the siRNAs,the more likely it is that accurate predictions can be
made by GRN. Therefore, in this current study we have
expanded our previous analysis by combining triplicated
eight time point SFD time course data with a much lar-
ger library of EC siRNA disruptant microarray data,
which was generated from the knockdown of 351 differ-
ent mRNA transcripts that encode proteins with a broad
range of functions in EC [11]. This expanded analysis
identified numerous GRN master regulators, many of
which were already known to play important roles in EC
biology. However, we noted one major master regulator
RNA named Vasohibin-1 (VASH1) that had not at the
time been extensively studied in EC apoptosis. There-
fore, we investigated the function of VASH1 in regulat-
ing mRNA abundance and in the process of EC
apoptosis. We targeted VASH1 using siRNA and then
used quantitative polymerase chain reaction (PCR) to
examine the abundance of 10 of the 31 mRNAs directly
downstream of VASH1 in the GRN. 7 of these 10
mRNAs were significantly up- or down-regulated in the
direction predicted by the GRN when VASH1 expression
was reduced. We also show that VASH1 is required for
the apoptotic response in EC treated with SFD.
Methods
Cell culture and siRNA transfection
Umbilical cords were collected with written informed
maternal consent and the approval of the Cambridge
(UK) Research Ethics Committee. Human Umbilical
Vein ECs (HUVECs) were isolated by collagenase diges-
tion, as previously described [31]. Cells were cultured in
fully supplemented media without antibiotics (basal
EBM-2 with a propriety mix of heparin, hydrocortisone,
epidermal growth factor, fibroblast growth factor, vascu-
lar endothelial growth factor, 2% foetal calf serum (FCS)
Lonza, Cambridge, UK), at 37°C/5% CO2. To carry out
siRNA transfection, HUVEC pools consisting of 10 bio-
logical isolates (of equal contribution) were prepared
using passage 3 cultured cells. The HUVEC pools were
plated in 6-well plates at 2.5 × 105 per well and left for
24hrs until approximately 70% confluent. siRNA transfec-
tion was carried out using pools of four siRNA duplexes
from Dharmacon Inc (Lafyette, Colorado, USA) and the
SiFectamine transfection reagent (ICVEC, London, UK)
according to the manufacturer’s instructions.
RNA processing and microarray preparation
RNA was extracted using TRIzolW reagent (Invitrogen,
London, UK). RNA quality was assessed using the
Agilent 2100 bioanalyser. Biotin labelled cRNA was gen-
erated and hybridised on the CodeLink Human Uniset
20K microarrays following the manufacturer’s instruc-
tions (Applied Microarrays, Tempe, Arizona, USA, for-
mally supplied by GE Healthcare).
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cDNA was synthesised from 1μg of total RNA using the
QuantiTect reverse transcription kit (Qiagen, Crawley,
UK), following the manufacturers protocol. Quantitative
PCR was carried out using an ABI 7700 sequence
analyser (Applied Biosystems, Warrington, UK). Reac-
tions were performed using the Applied Biosystems
universal master mix according to the manufacturers
instructions. The Taqman probe / primers used were:
VASH1 (Hs00208609_m1), SOX18 (Hs00746079_s1), PTX3
(Hs00173615_m1), FAM78A (Hs00604618_m1), PPARA
(Hs00231882_m1), SLC7A2 (Hs00952727_m1), BDNF
(Hs00542425_s1), MTSS1 (Hs00207341_m1), BTG2
(Hs00198887_m1), TNFSF-12 (Hs00356411_m1), FLT4
(Hs01047677_m1) and NTRK2 (Hs00178811_m1), all
from Applied Biosystems.
Previosuly generated microarray datasets used in this
study
The siRNA targeting of 351 different mRNA transcripts,
chosen for their importance in EC biology, including
transcription factors, signalling molecules, receptors and
ligands is described by Hurley et. al. [11]. The microarray
data from these 351 siRNA experiments is available from
Gene Expression Omnibus, reference GSE27869.
The generation of triplicated microarray data from an
eight time point HUVEC SFD time course has been
described previously [18]. Briefly, HUVEC RNA was
extracted at time points 0, 0.5, 1.5, 3, 6, 9, 12 and 24
hours after survival factor withdrawal (i.e. transfer from
complete media to basal EBM-2 media with no supple-
ments apart from 2% charcoal stripped serum), and
hybridised onto CodeLink Human Uniset 20K microar-
rays. The raw and normalised triplicate time course
microarray data has been deposited in Gene Expression
Omnibus, accession number GSE23067.
Data processing
CodeLink microarray quality was assessed using the
CodeLink Expression analysis software v4.0. The array
data were filtered to remove probes that did not contain
“Good” flags in 90% of the arrays, as measured by the
CodeLink Expression analysis software. The log base2
(log2)–transformed apoptosis time course data and 351
siRNA disruptant data were then both normalised using
the Loess method [32,33]. For the disruptant dataset
log2 ratios against a virtual median array were calculated
and these ratios were then z-transformed within each
microarray prior to network inference.
For the SFD time course data, we selected transcripts
concordantly regulated in abundance across the time-
course to used for GRN generation as previously
described [18]. Briefly, log ratios between each time
point and the first time point were calculated for alltranscripts. For each transcript at each time point
z-scores were then calculated by subtracting the log2
ratios from the mean of log2 ratios for that time point,
and dividing by the standard deviation of log2 ratios for
that time point. Transcripts were then selected that
had −2 ≤ z ≤+2 at ≥ two adjacent time points in the trip-
licate data set. This analysis was repeated using the last
time point instead of the first time point, and the union
of the RNA lists prodced by the analyses that used the
first and last timepoints was taken as the final list of
concordantly expresed RNAs. For comparison to this
z-score method, ANOVA was used to identify RNAs sig-
nificantly differntially expressed at two adjacent time
points relative to either the first or last time point, and
the empirical Bayes method of Tai and Speed [34] was
also applied. In addition, a statistically more complex
method was used to identify RNAs significantly differn-
tially expressed across the timecourse; generalised esti-
mating equations with a Markov correlation model were
fitted to the timecourse data. Contrasts were used to
identify linear relationships and quadratic trends within
the data using Matlab's GEEQBOX toolbox (http://www.
mathworks.com/products/matlab/). Thresholds for con-
cordant regulation were set using an absolute linear
coefficient of >21 (and linear q value <0.01) OR an abso-
lute quadratic coefficient of > 7 (and q value <0.01).
All other bioinformatic manipulations used the R soft-
ware package, (http://www.R-project.org), and unless
otherwise stated, multiple testing corrections were ap-
plied using the Benjamini and Hochberg method. Gene
ontology/pathway enrichment analyses were carried out
using Fatigo software [35], GeneSetDB [36], GATHER
(http://gather.genome.duke.edu/) and IPA (Ingenuity sys-
tems, www.ingenuity.com).
Apoptosis bayesian GRN generation and analysis
Apoptosis Bayesian networks were generated using the
methods of [37], with some modifications. Given the
relative sizes of the time-course and siRNA data sets, a
dynamic GRN generated from the time-course data was
used as a prior for GRN generated from the siRNA data
as described [37].
When estimating the time-course GRN from the apop-
tosis time course microaray data, a method of bootstrap-
ping was applied to the data. With 8 time points
(obtained 0, 0.5, 1.5, 3, 6, 9, 12 and 24hrs after serum
withdrawal) and 3 replicate microarray time course
experiments, there are 38 = 6561 possible combinations
to create combinatorial apoptosis time course datasets.
With such a large number of combinations, it is not
computationally viable to fit regression curves through
all combinations. Therefore the time course data used
for network estimation was generated from the random
resampling of 25 of the possible 6561 combinations as
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all genes. If D(c) is the 8 time points, with each time
point consisting of one of 3 replicates, then D(c) can be
randomly resampled with replacement 25 times from
the 6561 combinations so that D(c) (1 ≤ c ≤ 6561).
The bootstrap sample can therefore be defined as D* =
{D* (1),. . .., D* (25)}. Using this sample of 8 x 25 = 200
randomly resampled microarrays, the apoptosis GRN
was estimated. This bootstrapping procedure was
repeated 100 times to generate 100 different GRNs;
Ĝ*T
1,. . . .. Ĝ*T
100, where Ĝ*T
B is the estimated graph based
on the B-th bootstrap sample. To estimate the reliability
of the edges to be used as prior information, the boot-
strap probability of each edge was calculated as follows:
the reliability of the edge between the i-th gene to the
j-th gene (termed the bootstrap probability) is z 1ð Þij ¼
B e i; jð Þ∈G^BT ;B ¼ 1; . . . ; 100

on =100
 . A bootstrap prob-
ability threshold value was set at P = 0.8 and only those
edges that passed this threshold value were included in
the prior, Z1.
As described [37], a second prior (named the "array
prior", Z2), was also generated. This prior was based on
the up- or down-regulation of the abundance of all
mRNAs, represented as z-scores, analysed by the microar-
rays following siRNA-medaited targeting of the 351 genes.
Priors Z1 and Z2, were used when inferring a static
Bayesian network based on the disruptant dataset [37].
Again bootstrap resampling of the microarrays (100
times with replacement) was applied to improve the reli-
ability of edges included in the final network. The GRNs
were viewed and analysed using Cell Illustrator 5.0,
freely available software that can be downloaded from
http://www.cellillustrator.com.Quantification of apoptosis
Passage 3 HUVEC pools comprising equal numbers of
cells from 10 independant isolates were plated at 5 × 103
cells per well in a 96-well plate and cultured for 24 hrs
before siRNA transfection. Three different pools of 10
isolates were used for each assay. Cells were then left for
a further 24hrs before treatment with either survival fac-
tor deprived conditions of basal media without supple-
ments (EBM-2) or fully supplemented media without
antibiotics (EGM-2) for 24 hrs. Active caspase-3 and −7
were quantified using the Caspase-Glo 3/7 assay system,
following the manufacturer’s instructions (Promega,
Southampton, UK). The ADP:ATP ratio was calculated
using the Apo Glow assay (Lonza, Cambridge, UK),
according to the manufacture’s protocol. Assays were
carried out using a Fluostar Optima luminometer (BMG
Labtech, Aylesbury, UK). Statistical analysis was carried
out using a paired two-tailed t-test.Results
Gene selection methods for generating a bayesian GRN
to model EC apoptosis
For GRN modelling, we first identified mRNA transcripts
that were significantly regulated over the timecourse of
EC apoptosis. A z-score-based method for analysis of
timecourse data that we have reported previously ([18]
and see Methods) identified 486 significantly regulated
transcripts. We analysed these 486 RNAs using the Gene-
SetDB web tool [36] with the Gene Ontology (GO) and
WikiPathways databases. The RNAs were significantly
enriched for four main categories of annotation: (i) 'cell
cycle' (GO:0007049, 87 RNAs, p<0.0001 and WikiPath-
ways:WP179, 30 RNAs, p<0.0001), (ii) 'response to stress'
(GO:0006950, 39 RNAs, p<0.0001), (iii) 'apoptosis' (Wiki-
pathways:WP254, 7 RNAs, p=0.016) and (iv) 'immune
response' (GO:0006955, 21 RNAs, p<0.0001).
Bayesian GRN inference
In an attempt to better understand the relationships be-
tween the mRNAs concordantly regulated in abundance
during SFD, a Bayesian GRN was inferred. In theory, the
more data that GRN are based on, the the more accurate
their predictions can be. Therefore, for GRN generation
we used a combination of the SFD timecourse data and
a library of 351 siRNA disruptant microarrays. A total of
694 RNAs were used for GRN generation; the union of
the 486 RNAs concordantly regulated in abundance dur-
ing SFD and the 351 RNAs that were targeted by siRNA.
The methodology used to generate this Bayesian net-
work has been previously described [37] and is illu-
strated in Figure 1. An xml file describing this GRN can
be found in Additional file 1, which can be viewed using
the freely available software Cell Illustrator, and a text
file listing parent and child genes for the network edges
is given in Additional file 2.
Identification of GRN hubs
Hubs are highly connected nodes in GRNs and are can-
didate master regulators within the network structure.
In a directional GRN such as the Bayesian networks gen-
erated here, they can be identified on the basis of having
large numbers of downstream children. The distribution
of the number of children of all nodes in the GRN is
shown in the histogram in Additional file 3: Figure S1. A
list of the 50 hub genes with the largest number of chil-
dren (all with ≥20 children) in the network is shown in
Additional file 4. Given that the set of RNAs used for
GRN inference was already enriched for cell cycle and
stress response functions as described above, it is not
surprising that many of the GRN hubs appeared to be
involved in these processes. Only 53 of the 351 genes
that were targetted by siRNA knock-down to generate
the prior microarray data were significantly concordantly
serum withdrawal 
treatment of cells
siRNA treatment 
of cells
siRNA
siRNA
siRNA
replicated siRNA 
expression data
replicated 
timecourse 
expression data
dynamic Bayesian 
network inferred from 
time course data
directed relationships 
from siRNA data
KD1 KD2
prior
Bayesian network 
inferrence
prior
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Figure 1 Inference of a static Bayesian GRN. Bayesian GRNs were generated from two microarray datasets (1) time course of primary ECs in
conditions of SFD for 24 hours (8 time points in triplicate) to induce apoptosis and (2) disruptant dataset generated from the siRNA-mediated
knockdown of 351 transcripts. These two datasets were used in network inference. Bayesian GRNs were generated to maximise the posterior
probability, which consists of two priors; (a) the dynamic Bayesian GRN prior (generated from the time course data) and (b) the array prior
(measuring the relationships between the gene knockdowns and their regulatees, as measured by z-score in the 351 disruptant dataset), as well
as the marginal likelihood. This is the non-parametric regression through estimated edges based on the 351-disruptant dataset. The gene list of
694 transcripts chosen for network inference was selected based on (1) the transcripts regulated during the apoptosis time course and (2) the
351 siRNA targeted transcripts. Using the dynamic Bayesian GRN as a prior for the disruptant dataset, the relationships for the 694 transcripts
within the 351 disruptant dataset were inferred. Bootstrapping of the network prior and the estimated static network helped improve edge
reliability in the final network. The static apoptosis Bayesian GRN can be viewed using Cell Illustrator, which can be freely downloaded from
http://www.cellillustrator.com.
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timecourse (according to the same z-score criteria that
were used to select the 486 RNAs). Of these 53 RNAs, 10
are in the list of the to 50 hubs (ranked by the number of
downstream children).
We looked specifically at apoptosis-associated RNAs
in the GRN. Analaysis using the Fatigo software (http://
www.fatigo.org/) identified 505 probes in the Codelink
array data that encoded proteins involved in apoptosis,
58 of these probes were included as nodes in the
apoptosis gene network (highlighted in Additional file 5);
two of these (HSPE1 and BUB1B, with 28 and 23 chil-
dren respectively) were found in the top 50 hubs ranked
by number of downstream network children.
We also looked specifically at cell cycle-associated
RNAs in the GRN, since SFD induces cell cycle arrest in
addition to programmed cell death [29]. Of the 596 tran-
scripts on the Codelink array associated with cell cycle
regulation, 109 of these were included as nodes in the
network, with 9 located within the top 50 network hubs
ranked by number of downstream children.Downstream children of some GRN Hubs share common
functions
We assessed whether any of GRN hubs had downstream
children significantly enriched for specific biological
functions by comparing the downstream children of
each hub to the datatbases GO, KEGG and Transfac
using the GATHER web tool. The results of this analysis
are shown in Additional file 4 and examples are given
below. The hub transcript BLM (7th largest hub, 33 chil-
dren) encodes a DNA helicase that is important for mi-
totic DNA replication and DNA repair, and is mutated
in a broad range of cancers [38]. 16 of the 31 children of
BLM encoded proteins involved in aspects of cell cycle
regulation (GO:0008283, GATHER Bayes Factor = 22.3,
p = 3x10-9). Another hub gene encodes the cyclin
dependent kinase-binding protein CKS1B, which has 16
of its 49 GRN children associated with cell cycle control
(GO:0007049, GATHER Bayes Factor = 7.5 p = 0.007).
The hub KNTC2 encodes a kinetochore complex com-
ponent that functions as a spindle checkpoint signalling
molecule, and has 10 of its 18 children associated with
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p = 7.5 × 10-7). Another hub is GRN, encoding the gran-
ulin glycoprotein, a secreted regulator of cell growth and
survival. 10 of GRN’s 28 children are associated with the
response to cell stress (GO:0006950, GATHER Bayes
Factor = 8.6 p = 0.0005), and 5 with the regulation of
apoptosis (GO:0042981, GATHER Bayes Factor = 5.3
p = 0.004). The children emenating from the apoptosis-
associated hubs HSPE1 and BUB1B mentioned above
also shared comon functions, however the degree of en-
richment for these functions was not statistically signifi-
cant. Four of the 28 children of BUB1B were involved in
cell cycle regulation (CDC16, TPX2, NUSAP and BUB1)
and two in the regualtion of apoptosis (PIK3R1 and
CTNAL1). Similarly, three of the 23 children of HSPE1
were involved in cell cycle processes (RAD1, E2F4 and
MCM2) and two with cell death (TBP and FOSL2).
Identification of a novel GRN hub gene for further study
Evaluation of the literature revealed that several of the
most highly connected hubs (such as CKS1, 49 children
and MDK, 36 children), already had well-characterised
roles in cellular proliferation and apoptosis [39-41]. In
contrast, for VASH1 (9th ranked hub with 31 children)
there was no literature characterising its involvement in
EC apoptosis or cellular proliferation at the time of this
study. Several of the predicted GRN children of VASH1
are involved in the regulation of angiogenesis (e.g. FLT4,
BDNF, TIE1), apoptosis (e.g. TNFSF12, PPAR-α, CDC2L6)
and cell division (e.g. BTG2, CDKN1C). Therefore, given
that the purpose of this current study was to identifiy
novel regulators of EC apoptosis and since VASH1 had
previously been identified as a negative regulator of
angiogenesis [42,43] (suggesting a possible role in EC
apoptosis), VASH1 was selected as a candidate for fur-
ther investigation. Due to resource limitations no other
uncharacterised hubs were investigated in this study.
Figure 2 illustrates the positioning of the VASH1 hub inFigure 2 The VASH1 hub in the Bayesian GRN. The VASH1 hub represen
(highlighted in red) in the GRN topology. (b) Focussed analysis of the VASH
gene. (c) The normlaised non-log transformed expression profile of VASH1the GRN, the 31 children eminating from this hub, and
its expression profile over the SFD time course.
VASH1 would not have been prioritised as a candidate
gene for further study by using traditional statistical
methods that quantified the degree and variance of con-
cordant regulation of abundance over the SFD time
course. For example, when the concordant regulation of
RNAs were ranked using the z-score method or using
traditional ANOVA analysis to compare expression in
the first and last timepoints to all other timepoints,
VASH1 was ranked 71st and 63rd, respectively. The
empirical Bayes method of Tai and Speed using the
Hotelling T2-statistic [34] ranked VASH1 as 286th in
terms of evidence of non-constant temporal expression.
A more sophisticated method was also used, in which
generalised estimating equations (with Markov correl-
ation models) were fitted to the SFD time course data.
From this regression model contrasts were used to iden-
tify linear relationships and quadratic trends within the
data, and VASH1 ranked 175th.
Independent validation of directed edges emanating from
the VASH1 hub
To evaluate the RNAs hypothesised by the GRN to be
downstream of the VASH1 hub, 10 of the 31 children
were selected for independent validation using siRNA
knock-down and quantitative PCR. The selection was
based on known biological importance and reagent avail-
ability. The left column of panels in Figure 3 illustrates
the transcript profiles of VASH1 and selected children
over the SFD time course. In the case of MTSS1 (3a)
and SOX18 (3d), the children are positively co-regulated
with VASH1 over the apoptosis time course. In contrast,
BDNF (3g) and SLC7A2 (3j) are negatively co-regulated
with VASH1 over the time course. Correlation analysis
across the 351 siRNA disruptant dataset revealed that all
10 children correlated with VASH1 (correlation coeffi-
cients range from 0.5 – 0.8); the relationships betweents the 9th largest hub in the GRN. (a) Positioning of the VASH1 hub
1 hub, illustrating the parents and children emanating from this hub
mRNA in the three replicates across the SFD time course.
Figure 3 Regulation of selected VASH1 predicted children (a) Co-regulation of predicted child MTSS1 with VASH1 over the median
expression value of the triplicate apoptosis time course (b) Correlation of predicted child MTSS1 expression with VASH1 across the 351
disruptant dataset (c) Relative level of predicted child MTSS1 mRNA when VASH1 mRNA abundance is knocked down to ≤ 20% of its
initial value. The knockdown of VASG1 was carried out in both fully supplemented conditions (EGM2) and survival factor deprived conditions
(SFD), to assess the impact of the knockdown in both conditions. (d – f) as above for predicted child SOX18. (g – i) as above for predicted child
BDNF. (j – l) as above for predicted child SLC7A2.
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Figure 4 Quantitative PCR of siRNA-mediated knockdown of
VASH1 mRNA abundance to <20% of its initial level in three
HUVEC pools in both fully supplemented media conditions
(EGM2) and survival factor deprived conditions (SFD).
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siRNA disruptant microarrays are illustrated in scatter
plots in the middle panels of Figure 3. VASH1-SLC7A2
and VASH1-BDNF associated with negative correlation,
while the remaining children correlate positively with
VASH1 (Figure 3b, e, h and k). This correlation across
the 351 siRNA disruptant dataset concurred with the
co-regulation observed over the apoptosis time course in
Figure 3a, d, g and j.
Using siRNA to knockdown VASH1 mRNA to ≤ 20%
of its initial level appeared to significantly regulate 7 of
the 10 transcripts tested, in the direction predicted by
the GRN (Table 1). For example, MTSS1 and SOX18,
which were positively correlated with VASH1, were down-
regulated after knockdown of VASH1 (Figure 3c and 3f re-
spectively). In contrast, but as predicted by the GRN,
knockdown of VASH1 resulted in the up-regulation of
BDNF and SLC7A2, which were negatively correlated with
VASH1 (Figure 3i and Figure 3l). TNFSF12, PTX3 and
FAM78A did not show a clear result due to variable regu-
lation between EC replicate pools.
Regulation of apoptosis by VASH1
To evaluate whether the VASH1 hub is involved in the
process or regulation of EC apoptosis, siRNA was used
to knockdown VASH1 in three different pools of 10
HUVEC isolates for 24 hours before treatment with SFD
to induce apoptosis. After the 24 hour anti-VASH1
siRNA incubation, VASH1 mRNA abundance was
reduced to ≤ 20% of its initial level (Figure 4). Following
SFD there was a mean of 2.2 fold (t-test, p = 0.0009) less
active caspase-3 and −7 in the VASH1 knockdown EC
compared to the EC teated with non-targeting siRNATable 1 Fold change and P values of VASH1 and its
predicted children in fully supplemented conditions and
SFD conditions, after knockdown of VASH1
Fully Supplemented Media
(EGM2)
Survival Factor deprived
Media (SFD)
Fold Change P Value Fold Change P Value
VASH1 −7.59 0.0022 −17.50 0.0025
BDNF 3.90 0.4138 12.52 0.0339
BTG2 −1.65 0.1592 −3.10 0.0005
FAM78A −1.97 0.0577 −0.69 0.5752
FLT4 −1.99 0.0404 −3.67 0.0364
MTSS1 −1.82 0.0128 −3.97 0.0708
PPARA −1.92 0.0962 −2.79 0.0034
PTX3 −1.04 0.4932 0.54 0.6942
SLC7A2 1.96 0.1087 2.30 0.0237
SOX18 −1.41 0.5587 −3.81 0.0002
TNFSF12 0.46 0.5499 −1.82 0.0223
P values are from a paired t test.controls (Figure 5a). Repetition of this assay in two add-
itional pools of HUVEC isolates in which VASH1 was
once again knocked down to ≤ 20% of its initial level
produced a similar result - following SFD there was on
average 1.8 fold (p = 0.03) less active caspase-3 and −7
following VASH1 knockdown than in control cells (data
not shown). The observed level of active caspase-3 and −7
in HUVEC in fully supplemented conditions was similar
in VASH1 knockdown and control cells (data not shown).
The activation of caspase-3 and −7 only represents
one part the complex process of apoptosis. Since apop-
tosis is an energy driven process, the ADT:ATP ratio
was also calculated in the same HUVEC pools. A
marked reduction in the mean ADP:ATP ratio was
observed in the VASH1 knockdown EC relative to the
siRNA control EC following SFD in two independent
experiments (12.4 fold, P=0.004 and 3.4 fold, P=0.005,
respectively, Figure 5b). Again, no significant difference
was observed between the VASH1 knock down EC and
controls in fully supplemented conditions (data not
shown). Taken together, these results suggest that
VASH1 may play a significant role in SFD-induced apop-
tosis of HUVECs.
The inverse expression relationship between VASH1
and its validated child BDNF, and the known role of
BDNF as a survival factor, suggests the hypothesis that
up-regulation of BDNF when VASH1 is knocked down
may promote survival in these cells. However, the treat-
ment of the HUVEC pools with 100nM recombinant
BDNF at 24 hours post-transfection (at the same point
as treatment with either fully supplemented media or
SFD conditions), did not induce significant rescue from
SFD-induced cell death, as measured by both the quanti-
fication of active caspase-3 and 7 and the ADP:ATP ratio
(data not shown).
Figure 5 (a) Quantification of active caspase-3 and −7 in three independent pools of 10 HUVEC isolates treated with either a non-
targeting siRNA for 48hrs or siRNA against VASH1 for 48 hrs. HUVECs were treated 24hrs post transfection with survival factor deprived (SFD)
conditions for 24hrs before measurement. A significant difference was observed between the VASH1 knockdown and the siRNA control in the
SFD condition (P = 0.0009, paired two tailed t-test). (b) Quantification of the ADP:ATP ratio in three pools of 10 HUVEC isolates treated with either
a non-targeting siRNA for 48hrs or siRNA against VASH1 for 48hrs. HUVECs were treated 24hrs post transfection with SFD conditions for 24hrs
before measurement (P = 0.02). P = Pool.
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This study used Bayesian GRN technology and micro-
array data to model the regulatory interactions after
serum factor deprivation of EC, which induces cell cycle
arrest and apoptosis. We applied GRN analysis to com-
bined time course microarray data following serum
deprivation-induced apoptosis of EC, and a large micro-
array data set generated from 351 targeted EC siRNA
disruptions, in order to identifiy new information about
gene regulatory relationships during EC apoptosis.GRN topology and limitations
We have used GRN analysis to identify hubs, which po-
tentially act as master regulators of the expression of
downstream RNAs in EC. For one hub, VASH1, we then
confirmed the concordant regulation of a subset of
downstream children as hypothesised by the GRN, and
an impact on apoptosis. VASH1 protein has previously
been identified as a negative feedback regulator of angio-
genesis, and is induced through signalling via VEGFR2
and protein kinase C [43,44]. These findings are consist-
ent with a role for VASH1 as a key regulator of EC biol-
ogy, and with the position of VASH1 as a hub in the
GRN with an effect on EC apoptosis.
We suggest that GRN analysis may provide a useful
compliment to traditional analysis of microarray or
RNAseq data, especially for identifying putative master-
regulators for further study. We showed that alternative
methods to identify apoptosis-associated RNAs from
time course expression data were unlikely to have
selected VASH1 as a candidate gene for subsequent
functual analaysis. Methods based on: z-scores, ANOVA
and empirical Bayes all failed to prioritise VASH1.However, we also recognise the potential limitations of
gene network analysis. Firstly, only a few of the tran-
scripts that encode protein mediators of apoptosis are
expected to be up- or down-regulated during relatively
short time points of SFD-induced apoptosis [29] to a
sufficint degree to be included in this analysis, and SFD
is only one of many inducers of apoptosis. Therefore,
only a subset of known apoptosis-associated genes are
accessible to this type of GRN study. Secondly, many
genes known to be important in the apoptotic process
may not be “master regulators” detectable as hubs in
gene networks, which requires that they rapidly regulate
the abundance of large numbers of downstream RNAs.
Since we used timecourse microarray data from EC cells
treated with survival factor deprivation, we expected to
identify only master regulators that were specifically
related to the molecular processes that occur during this
timecourse. To be identified as a "hub" in the gene net-
work, both an RNA, and its downstream "child" RNAs,
must be significantly concordantly regulated over the
timecourse. Therefore, not all RNAs important for EC
biology will be concordantly regulated during this specia-
lised type of apoptosis, and even if they are, they will not
be identified as hubs unless they rapidly regulate the
abundance of large numbers downstream RNA tran-
scripts. Thirdly, like all in silico modelling based on micro-
array or RNAseq data, results of special interest from
GRN analysis need to be confimred using laboratory
experiments as we have done here.Inference of local relationships within the network
Several GRN methods have proven informative for iden-
tifying regulatory hubs or cohorts of co-expressed genes
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portant disease processes [10,45-47]. However, most of
these methods fall short of inferring directional relation-
ships at a local level. Therefore, having identified the
VASH1 hub based on network topology, we examined
the GRN predictions surrounding this hub in more de-
tail. Using siRNA we knocked down VASH1 mRNA and
determined the effect on expression levels of down-
stream mRNAs for ten out of VASH1's 31 GRN children.
Seven out of the ten children tested were significantly
up- or down-regulated in the direction predicted by the
GRN (see Table 1). The lack of clear influence of VASH1
knock-down on three child-transcripts may be due to
several factors: (i) Reducing VASH1 RNA may have little
effect on the abundance of those gene network children
of VASH1 that are strongly influenced by other parents
in addition to VASH1 - the undiminished effects of these
other parents would be expected to hide the effect of re-
ducing VASH1 expression. (ii) Regulatory relationships
that are not represented in the GRN may influence the
expression of some of VASH1's gene network children,
(iii) Despite best efforts, the effects of experimental noise
and unintended model over-fitting are likely to have
introduced error in the inference process. These issues
are further described in our recent publications [48,49].
It is possible that additional siRNA data may improve
the accuracy of GRNs around VASH1, which is a subject
for future research.
Whether the observed level of concordance between the
network predictions and the results of experimental
VASH1 knockdown only surrounds the major hubs within
the Bayesian network structure, or is randomly distributed
throughout the network, requires further investigation.
Due to resource constraints we have only evaluated a mi-
nority of edges downstream of a single hub. This is clearly
not enough to draw any general conclusions about GRNs
and their reliability. Given further resources, we would
like to evaluate the relationships between VASH1 and the
remaining 21 children that we have not yet tested, as well
as the relationships between several other nodes and their
children. To more completely test local network relation-
ships we would ultimately need to simultaneously perform
siRNA-mediated "knockdown" of all the gene network
parents of each VASH1 child then measure the effect on
VASH1 child abundance. In addition, as computational
capabilities improve, it would be interesting to re-engineer
GRNs with the inclusion of more of the replicate arrays
and compare the reliability with that of the current net-
work model. Nevertheless, given the early stage of this
technology, the fact that only one (VASH1) of several par-
ents of the evaluated VASH1 children was knocked down,
and the fact that there are data missing from the network
(due to computational constraints it contains only 694
transcripts), these current findings appear promising.Functional significance of the VASH1 gene network hub
To investigate whether the VASH1 hub was biologically
relevant during endothelial apoptosis, we used siRNAs
targeted against VASH1 to reduce mRNA abundance to
<20% of its initial level and quantified the level of apop-
tosis in these cells under conditions of SFD relative to
control cells transfected with an irrelevant siRNA. The
measurement of active caspase-3 and −7 and the ADP:
ATP ratio were used as end-points and the knock-down
of VASH1 conferred resistance to the pro-apoptotic
stimulus of serum deprivation. This confirms a role for
VASH1 in the process of EC apoptosis, and is consistent
with a study published since this research was conducted
that shows over expression of VASH1 induced apoptosis
in proliferating human fibroblasts [50].
Although the mechanism by which VASH1 regulates
EC survival is beyond the scope of this study, it is intri-
guing to examine the function of VASH1’s GRN children
in the anticipation that this may suggest how VASH1
acts. Ingenuity Pathways Analysis (IPA) suggested that
the VASH1 GRN children are significantly enriched for
genes associated with angiogenesis (FDR = 0.025), in-
cluding several well-known angiogenic regulators; BDNF,
DLL4 (delta-like 4), FLT4 (vegfr-3), PPARA, PTX3,
SOX18, TIE1, and TNFSF12 (tweak). Several of the
VASH1 children have previously been associated with
the linked control of proliferation and apoptosis e.g.
CDKN1C (p57/kip2), CDC2L6, GSN (gelsolin) and DLL4.
It is interesting that 20 of the 31 VASH1 children have
binding sites for members of the E2F transcription factor
family in their promoters (V$E2F1_Q3, FDR = 0.002);
experiments to assess whether E2F transactivation is
regulated by VASH1 may be worthwhile.
One mechanistic hypothesis was investigated in this
study. The autocrine action of BDNF in cellular processes
including angiogenesis, proliferation, differentiation and
survival is well documented [51-53]. Therefore, the in-
verse relationship between VASH1 and its validated child
BDNF, suggests a hypothesis that upregulation of BDNF
when VASH1 is knocked down may promote survival.
However, recombinant BDNF was unable to rescue the
cells from SFD induced death. It is possible that the
chosen concentration of recombinant BDNF (100nM) and
time point of administration were not optimal. However,
the results suggest that it is unlikely that the mechanism
of VASH1 action in EC apoptosis is as simple as up-
regulation of BDNF. The relatively low expression of the
BDNF high affinity (TrkB) and the low affinity (p75NTR)
receptors observed in the microarray data from these cells
(TrkB, percentile rank expression = 0.142113 and p75NTR,
percentile rank expression = 0.414449 in healthy HUVEC)
may also explain why exogenous BDNF was not effective.
Since this study was conducted, several publications
have described the role of VASH1 in regulating EC
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uration [50,54] [55], as well as a potentially wider func-
tional role in other cell types [56]. In addition, VASH1
may interact in complex functional networks with
related proteins such as VASH2 to regulate angiogensis
and EC survival differently in distinct angiogenic
mechanisms [57]. Whatever its mechanism of action,
VASH1 appears to be associated with angiogenesis in
pathology [43,58], and further investigation of the mo-
lecular networks that surround VASH1 seem highly
worthwhile.
Conclusion
GRN analysis is able to supplement the reductionist
methods of traditional molecular biology, providing test-
able hypotheses about the synergistic actions and inter-
actions of multiple molecules [59]. We therefore applied
Bayesian GRN methods to further our understanding of
the regulation of EC apoptosis and proliferation. The
SFD Bayesian GRN generated in this study identified
VASH1 as a candidate master regulator, which we found
was functionally important during EC apoptosis. We also
found that several individual directed edges emanating
from VASH1 in the GRN appeared to operate in ECs. We
hope that in future studies the datasets we describe here
can be used by other researchers to identify additional
candidate master regulators for laboratory evaluation.
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